Cerity Partners
NAGE

Cerity Partners’s Niagen Bioscience NAGE Stock Holding History

Cerity Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8K Sell
14,991
-1,586
-10% -$6.44K ﹤0.01% 3304
2026
Q1 		$73.1K Buy
+16,577
New +$89.5K ﹤0.01% 3061

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cerity Partners's NAGE Position: Q2 2026 in Review

Cerity Partners reduced its Niagen Bioscience (NAGE) stake by 9.6% in Q2 2026, selling an estimated $6.44K and leaving 14,991 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

Cerity Partners first reported a position in NAGE in Q1 2026 and has held it in 2 quarters since. The position peaked at $73.1K in Q1 2026. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Cerity Partners held 14,991 shares of Niagen Bioscience worth $47.8K as of Q2 2026.
  • Cerity Partners sold 1,586 Niagen Bioscience shares in Q2 2026, an estimated $6.44K.
  • Niagen Bioscience made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3304 holding.
  • Cerity Partners first reported a position in Niagen Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Cerity Partners's Niagen Bioscience position peaked at $73.1K in Q1 2026.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.